Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effec...
05 Mai 2020 - 3:00PM
Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader
in the growing field of cancer metabolism-based therapeutics, today
announced that it has entered into a research collaboration with
Roswell Park Comprehensive Cancer Center. Through this
collaboration, researchers will evaluate the effects of CPI-613®
(devimistat) with or without chemotherapy agents, including
oxaliplatin/cisplatin/5-FU/carboplatin/taxol, on esophageal cancer
cells.
“With our focus on hard-to-treat cancers,
especially those in the gastrointestinal tract, research in
treating esophageal cancer has been a significant goal for us,”
said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals.
“The high standards and caliber of researchers at Roswell Park made
this research possible, and we are honored to partner with
them.”
Rafael has several active clinical trials
focusing on cancers in the gastrointestinal tract. Its Phase 3
clinical trial in metastatic pancreatic cancer (AVENGER 500) is
enrolling significantly ahead of schedule, with more than 80% of
the patients needed for the trial already enrolled. The company
also has Phase 1 and 2 clinical trials in pancreatic cancer, as
well as a Phase 1 trial in colorectal cancer.
“Through this research, we expect to determine
whether devimistat inhibition of PDH and KGDH with or without
chemotherapy synergistically decreases DNA replication and
increases cell death in esophageal cancer cells,” said Steven
Hochwald, M.D., M.B.A., Chief of Gastrointestinal/Endocrine Surgery
and Professor of Oncology at Roswell Park Comprehensive Cancer
Center in Buffalo, N.Y. He is also the principal investigator on
the preclinical study. “We will focus on the effects of devimistat
on proliferation and cell death using esophageal cancer cell
models.”
Collaborative clinical trials in patients are
planned after the initial analyses are completed.
About CPI-613® (devimistat) CPI-613®
(devimistat) is a first-in-class clinical lead compound of Rafael,
which targets enzymes that are involved in cancer cell energy
metabolism and are located in the mitochondria of cancer cells.
Devimistat is designed to target the mitochondrial tricarboxylic
acid (TCA) cycle, a process essential to tumor cell multiplication
and survival, selectively in cancer cells. Devimistat substantially
increases the sensitivity of cancer cells to a diverse range of
chemotherapeutic agents. This synergy allows for potential
combinations of devimistat with lower doses of these generally
toxic drugs to be more effective with lower patient’s side effects.
Combination with devimistat represent a diverse range of
opportunities to substantially improve patient’s benefit in many
different cancers. The U.S. Food and Drug Administration (FDA) has
given Rafael approval to initiate pivotal Phase 3 clinical trials
in pancreatic cancer (AVENGER 500) and acute myeloid leukemia
(ARMADA 2000), and has designated devimistat as an orphan drug for
the treatment of pancreatic cancer, acute myeloid leukemia,
myelodysplastic syndrome, peripheral T-cell lymphoma and Burkitt’s
lymphoma. The EMA has granted orphan drug designation to devimistat
for pancreatic cancer and acute myeloid leukemia.
About Rafael Pharmaceuticals, Inc.Rafael
Pharmaceuticals is a leader in the growing field of cancer
metabolism. The company is developing a new, first-in-class
category of metabolic oncology therapeutics that attack
hard-to-treat cancers by targeting the metabolic processes the
disease needs to survive, grow and proliferate. Rafael
Pharmaceuticals’ lead compound, CPI-613® (devimistat), is a highly
selective, well-tolerated and effective anti-cancer agent that is
being evaluated in ongoing and completed Phase 1, 2 and 3 clinical
trials. Devimistat has been granted orphan drug status by the FDA
for the treatment of pancreatic cancer, acute myeloid leukemia
(AML), myelodysplastic syndrome (MDS) and Burkitt’s and peripheral
T-cell lymphomas. The Company's investors include Rafael Holdings,
Inc. (NYSE AMERICAN: RFL). For more information, please visit
www.rafaelpharma.com.
Safe Harbor StatementThis press release
contains forward-looking statements. These statements relate to
future events or the company’s future financial performance. In
some cases, you can identify forward-looking statements by
terminology such as "may", "will", "should", "expect", "plan",
"anticipate", "believe", "estimate", "predict", "potential" or
"continue", the negative of such terms, or other comparable
terminology. These statements are only predictions. Actual events
or results may differ materially from those in the forward-looking
statements as a result of various important factors. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, such statements should not be regarded
as a representation by the company, or any other person, that such
forward-looking statements will be achieved. The business and
operations of the company are subject to substantial risks which
increase the uncertainty inherent in forward-looking statements. We
undertake no duty to update any of the forward-looking statements,
whether as a result of new information, future events or
otherwise.
In light of the foregoing, readers are cautioned
not to place undue reliance on such forward-looking
statements.###
Rafael Media Contact:Holly
Duganrafael@antennagroup.com (201) 465-8019
Roswell Park Media Contact:Annie
Deck-Millerannie.deck-miller@roswellpark.org(716) 602-5817
Rafael (AMEX:RFL)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Rafael (AMEX:RFL)
Historical Stock Chart
Von Jun 2023 bis Jun 2024